Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07181837 · ClinicalTrials.gov registry record · Phase 1
A Phase 1/2 Study of the Safety and Efficacy of MVX-220 in Angelman Syndrome
A Phase 1 study of Angelman Syndrome, sponsored by MavriX Bio.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 12
- Enrollment target
- 3
- Study locations
NCT07181837 is a Phase 1 study of Angelman Syndrome that is actively recruiting participants, run by MavriX Bio. The registered enrollment target is 12 participants, below the 125-participant average among 11 other Angelman Syndrome trials with a reported enrollment target (90% lower). The trial reports 3 study locations across 3 states.
The verdict
NCT07181837, a Phase 1 study of Angelman Syndrome, is actively recruiting participants, sponsored by MavriX Bio.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 12 participants
- Enrollment target
- 3
- Study locations
Study Summary
The purpose of this study is to evaluate the safety and efficacy of MVX-220 gene therapy in children and adults with Angelman syndrome with UBE3A gene deletion, uniparental disomy, or imprinting center defect genotypes.
Conditions Studied
Interventions
- GENETIC MVX-220
Study Locations (3)
California
- Cedars-Sinai Medical Center - Los Angeles
Illinois
- Rush University Medical Center - Chicago
Massachusetts
- Boston Children's Hospital - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2025-10-29 |
| Est. Completion | 2031-05-31 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07181837
The ClinicalTrials.gov registry entry for NCT07181837 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 125-participant average among 11 other Angelman Syndrome trials with a reported enrollment target (90% lower). The listed sponsor is MavriX Bio, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Angelman Syndrome appearing as the primary indexed condition, and to 1 intervention - of which MVX-220 is the first listed.
NCT07181837 reports 3 study locations spanning 3 distinct geographic areas - top geographies include California, Illinois, Massachusetts.
Frequently Asked Questions
What is clinical trial NCT07181837 about?
NCT07181837 is a clinical study titled "A Phase 1/2 Study of the Safety and Efficacy of MVX-220 in Angelman Syndrome". The purpose of this study is to evaluate the safety and efficacy of MVX-220 gene therapy in children and adults with Angelman syndrome with UBE3A gene deletion, uniparental disomy, or imprinting center defect genotypes.
What is the current status of trial NCT07181837?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 12 participants. The study started on 2025-10-29. Estimated completion is 2031-05-31.
What conditions does trial NCT07181837 study?
This clinical trial studies the following conditions: Angelman Syndrome.
What interventions are being tested in trial NCT07181837?
The interventions under investigation include: MVX-220 (GENETIC).
Who is sponsoring clinical trial NCT07181837?
This trial is sponsored by MavriX Bio, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07181837 being conducted?
This trial has 3 study locations across California, Illinois, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Angelman Syndrome
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
HALOS: A Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of Multiple Ascending Doses of ION582 in Participants With Angelman Syndrome
RECRUITING · Phase 1
-
A Study to Investigate the Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of RO7248824 in Participants With Angelman Syndrome (AS)
COMPLETED · Phase 1
-
Angelman Syndrome Natural History Study
RECRUITING
-
REVEAL: A Phase 3 Study of ION582 in Angelman Syndrome
RECRUITING · Phase 3
-
Web Intervention for Parents of Youth With Genetic Syndromes (WINGS)
RECRUITING · NA
-
A Safety and Efficacy Study of GTX-102 in Subjects With Deletion- or Nondeletion-type Angelman Syndrome (AS)
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.